Proteomic Analysis of Low-Grade Serous Ovarian Cancer and Comparing It with Non-cancerous Ovarian

被引:1
|
作者
Bashizadeh Fakhar H. [1 ]
Rezaie-Tavirani M. [1 ]
Zali H. [2 ]
Darkhaneh R.F. [3 ]
Nejad E.K. [4 ]
Aghazadeh M.H. [5 ]
机构
[1] Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran
[2] Proteomics Research Center, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran
[3] Department of Obstetrics and Gynecology, Reproductive Health Research Center, Guilan University of Medical Sciences, Rasht, Guilan
[4] Department of Biostatistics, Guilan Road Truma Research Center, Guilan University of Medical Sciences, Rasht
[5] Azad Medical University, Tehran
关键词
Comparison; Low-grade serous ovarian cancer; Non-cancerous ovarian; Proteomics;
D O I
10.1007/s40944-018-0187-8
中图分类号
学科分类号
摘要
Background: In Iran, ovarian cancer is the eighth most common cancer. Serous is considered as the most common of all ovarian cancers. It is usually deadly due to late diagnosis. Moreover, as all studies so far have considered metastatic or high-stage ovarian cancer, this study sought low-grade ovarian serous in human, which is of high importance and aimed at obtaining protein biomarkers that may be useful in diagnosis and treatment of ovarian serous cancer. Materials and Methods: In this experimental study, ten patients with proved low-grade serous ovarian cancer and ten women without ovarian cancer, healthy, and cancerous tissue samples were obtained to perform proteomics. All tissue proteins were purified using standard separation methods, and proteins were separated using two-dimensional electrophoresis. Healthy and tumorous tissue proteomes were compared, and the extent of protein expression was analyzed. Results: This study identified 212 proteins, 41 of which had changes in protein expression in cancer state. The expression of eight proteins was suppressed, and five proteins were expressed in cancerous group. Thirteen proteins in cancer sample showed increase in expression and 15 proteins reduced expression in cancerous tissue. Conclusion: It seems that in this disease, the expression of a large number of proteins in cancerous tissues changed, most of them decreased or not expressed at all. These changed proteins can be effective as biomarker in diagnosis and treatment of this disease. © 2018, Association of Gynecologic Oncologists of India.
引用
下载
收藏
相关论文
共 50 条
  • [41] Characterizing the genomic and immunologic landscape of serous borderline tumors and low-grade serous ovarian cancer
    Krishnan, Rahul
    Bilecz, Agnes
    Herbst, Paula
    Shimizu, Aasa
    Schweizer, Lisa
    Jaeger, Ellen
    Godden, Jen
    Stoppler, Melissa
    Yamada, Diane
    Lengyel, Ernst
    CANCER RESEARCH, 2024, 84 (05)
  • [42] Trametinib for patients with recurrent low-grade serous ovarian cancer: A cost-effectiveness analysis
    Piao, Huiling
    Wu, Meiyu
    Qin, Shuxia
    Tang, Zhiyao
    Zhou, Guangliang
    Wan, Xiaomin
    Zuo, Xiaocong
    GYNECOLOGIC ONCOLOGY, 2023, 168 : 17 - 22
  • [43] Low-grade serous ovarian cancer: expert consensus report on the state of the science
    Grisham, Rachel N.
    Slomovitz, Brian M.
    Andrews, Nicole
    Banerjee, Susana
    Brown, Jubilee
    Carey, Mark S.
    Chui, Herman
    Coleman, Robert L.
    Fader, Amanda N.
    Gaillard, Stephanie
    Gourley, Charlie
    Sood, Anil K.
    Monk, Bradley J.
    Moore, Kathleen N.
    Ray-Coquard, Isabelle
    Shih, Ie-Ming
    Westin, Shannon N.
    Wong, Kwong-Kwok
    Gershenson, David M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (09) : 1331 - 1344
  • [44] Mutations in low-grade serous ovarian cancer and response to BRAF and MEK inhibitors
    Moujaber, Tania
    Etemadmoghadam, Dariush
    Mapagu, Cristina
    Kennedy, Catherine
    Chiew, Yoke-Eng
    Kan, Casina
    Nevins, Nikilyn
    Srirangan, Sivatharsny
    Fereday, Sian
    Traficante, Nadia
    Bowtell, David
    Balleine, Rosemary
    Harnett, Paul
    deFazio, Anna
    CANCER RESEARCH, 2018, 78 (13)
  • [45] Risk stratification using hotspot genotyping in low-grade serous ovarian cancer
    Wohlmuth, C.
    Tone, A.
    Daghrach, A.
    Stickle, N.
    Virtanen, C.
    Brown, T. J.
    May, T.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 36 - 37
  • [46] Low-grade serous ovarian cancer: Recent advances and future directions.
    Grisham, Rachel N.
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 27 - 27
  • [47] Racial and ethnic differences in the mutational landscape of low-grade serous ovarian cancer
    Ahsan, Muhammad Danyal
    Webster, Emily M.
    Levi, Sarah R.
    Nguyen, Natalie T.
    Cubillos-Ruiz, Juan R.
    Cantillo, Evelyn
    Chapman-Davis, Eloise
    Frey, Melissa K.
    Holcomb, Kevin
    CANCER RESEARCH, 2023, 83 (07)
  • [48] Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions
    Rachel N. Grisham
    Gopa Iyer
    Current Treatment Options in Oncology, 2018, 19
  • [49] Molecular changes driving low-grade serous ovarian cancer and implications for treatment
    Kelliher, Lucy
    Yoeli-Bik, Roni
    Schweizer, Lisa
    Lengyel, Ernst
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024,
  • [50] Factors associated with the involvement of lymph nodes in low-grade serous ovarian cancer
    Durmus, Yasin
    Meydanli, Mehmet M.
    Akilli, Huseyin
    Kayikcioglu, Fulya
    Gungorduk, Kemal
    Akbayir, Ozgur
    Taskin, Salih
    Celik, Husnu
    Ayhan, Ali
    JOURNAL OF SURGICAL ONCOLOGY, 2022, 125 (02) : 264 - 272